Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 12/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7936073 | 0.99 | HTR1A (0.45) | HTR1ASLC6A4RAB9AHPGDALDH1A1 | |
| Cadaverine Tartrate SCHEMBL6245775 | 0.93 | HTR1A (0.41) | HTR1ASLC6A4RAB9AHPGD | |
| SCHEMBL7932463 | 0.81 | HTR1A (0.71) | HTR1ASLC6A4 | |
| SCHEMBL27640871 | 0.74 | HTR1A (0.54) | HTR1ASLC6A4RAB9A | |
| SCHEMBL8718022 | 0.72 | HDAC3 (0.43) | HTR1ASLC6A4HPGD | |
| SCHEMBL8242266 | 0.67 | ACHE (0.38) | HTR1ASLC6A4 | |
| SCHEMBL21189313 | 0.65 | MAOB (0.49) | RAB9AHPGDALDH1A1 | |
| SCHEMBL21189388 | 0.63 | NPC1 (0.44) | RAB9AHPGDALDH1A1 | |
| SCHEMBL7616889 | 0.63 | HTR1A (0.80) | HTR1ASLC6A4 | |
| SCHEMBL7616883 | 0.63 | HTR1A (0.80) | HTR1ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1423098-A1 | A NEW EXTENDED RELEASE ORAL DOSAGE FORM | AstraZeneca AB (SE) | 2004-06-02 | — | — | EP | claimed |
| WO-2003017982-A1 | A NEW EXTENDED RELEASE ORAL DOSAGE FORM | ASTRAZENECA AB (SE) | 2003-03-06 | — | — | WO | claimed |
| WO-2003017984-A1 | A NEW EXTENDED RELEASE ORAL DOSAGE FORM | ASTRAZENECA AB (SE) | 2003-03-06 | — | — | WO | claimed |
| EP-1133292-A1 | A NEW PHARMACEUTICAL COMPOSITION | AstraZeneca AB (SE) | 2001-09-19 | — | — | EP | claimed |
| WO-2000032187-A1 | A NEW PHARMACEUTICAL COMPOSITION | ASTRAZENECA AB (SE) | 2000-06-08 | — | — | WO | claimed |
| US-6858645-B2 | Tartrate salts of (R) -3-N,N- dicyclobutylamino-8-fluoro-3,4-dihydro-2H-1- benzopyran-5-carboxamide | ASTRAZENECA AB (SE) | 2005-02-22 | — | — | US | disclosed |
| WO-2003017984-A1 | A NEW EXTENDED RELEASE ORAL DOSAGE FORM | ASTRAZENECA AB (SE) | 2003-03-06 | — | — | WO | disclosed |
| US-6472423-B1 | Pharmaceutical composition | ASTRAZENECA AB (SE) | 2002-10-29 | — | — | US | disclosed |
| EP-1133292-A1 | A NEW PHARMACEUTICAL COMPOSITION | AstraZeneca AB (SE) | 2001-09-19 | — | — | EP | disclosed |
| EP-1133292-A1 | A NEW PHARMACEUTICAL COMPOSITION | AstraZeneca AB (SE) | 2001-09-19 | — | — | EP | disclosed |
| WO-2000032187-A1 | A NEW PHARMACEUTICAL COMPOSITION | ASTRAZENECA AB (SE) | 2000-06-08 | — | — | WO | disclosed |
| WO-2000032187-A1 | A NEW PHARMACEUTICAL COMPOSITION | ASTRAZENECA AB (SE) | 2000-06-08 | — | — | WO | disclosed |
| EP-0984952-A1 | A NEW SALT | Astra Aktiebolag (SE) | 2000-03-15 | — | — | EP | disclosed |
| EP-0975618-A1 | A NEW PROCESS | Astra Aktiebolag (SE) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998054166-A1 | A NEW SALT | ASTRA AKTIEBOLAG (SE) | 1998-12-03 | — | — | WO | disclosed |
| WO-1998046586-A1 | A NEW PROCESS | ASTRA AKTIEBOLAG (SE) | 1998-10-22 | — | — | WO | disclosed |